Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses

Published:2020-10-14 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Kidman Joel,Principe Nicola,Watson Mark,Lassmann Timo,Holt Robert A.,Nowak Anna K.,Lesterhuis Willem Joost,Lake Richard A.,Chee Jonathan

Funder

National Health and Medical Research Council

Cancer Council Western Australia

Raine Medical Research Foundation

New South Wales Workers' Compensation Dust Disease Board

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference93 articles.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma;Hodi;New Engl J Med,2010

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer;Brahmer;New Engl J Med,2015

3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer;Reck;New Engl J Med,2016

4. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma;Ansell;New Engl J Med,2015

5. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma;Nghiem;New Engl J Med,2016

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of Wilms’ tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed;Annals of Hematology;2024-09-11

2. Human TCR repertoire in cancer;Cancer Medicine;2024-09

3. Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy;Cancer Research Communications;2024-08-01

4. BCR, not TCR, repertoire diversity is associated with favorable COVID-19 prognosis;2024-06-11

5. First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours;BMJ Oncology;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3